Leading the Way in Life Science Technologies

GEN Exclusives

More »

GEN News Highlights

More »
Jan 12, 2007

BioInvent and Genentech Partner on Cardiovascular Disease Deal Worth Up to $190M

  • BioInvent and Genentech will co-develop and commercialize BioInvent’s antibody candidate, BI-204, for the potential treatment of multiple cardiovascular conditions.

    Genentech will make an upfront payment of $15 million. BioInvent could receive further milestone payments of up to $175 million as well as royalties on sales in North America.

    Under the terms of the agreement, Genentech and BioInvent will be jointly responsible for clinical development. Genentech will be responsible for and will solely control any commercialization of the drug in North America. BioInvent will be responsible for and will solely control commercialization in the rest of the world. 

    “Retaining the rights to the product outside of North America gives us an opportunity to increase our participation and involvement in the product’s success,” says BioInvent’s CEO Svein Mathisen.



Be sure to take the GEN Poll

Scientifically Studying Ecstasy

MDMA (commonly known as the empathogen “ecstasy”) is classified as a Schedule 1 drug, which is reserved for compounds with no accepted medical use and a high abuse potential. Two researchers from Stanford, however, call for a rigorous scientific exploration of MDMA's effects to identify precisely how the drug works, the data from which could be used to develop therapeutic compounds.

Do you agree that ecstasy should be studied for its potential therapeutic benefits?

More »